These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15881609)

  • 1. Characterization of the force effect of aqueous and oily eye drops.
    Müller F; Wagner M; Neubert RH
    Pharmazie; 2005 Apr; 60(4):283-7. PubMed ID: 15881609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tear fluid-eye drops compatibility assessment using surface tension.
    Hotujac Grgurević M; Juretić M; Hafner A; Lovrić J; Pepić I
    Drug Dev Ind Pharm; 2017 Feb; 43(2):275-282. PubMed ID: 27645109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the physico-chemical properties of ophthalmic viscolysers on the weight of drops dispensed from a flexible dropper bottle.
    Van Santvliet L; Ludwig A
    Eur J Pharm Sci; 1999 Mar; 7(4):339-45. PubMed ID: 9971918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micellar solutions of triblock copolymer surfactants with pilocarpine.
    Pepić I; Jalsenjak N; Jalsenjak I
    Int J Pharm; 2004 Mar; 272(1-2):57-64. PubMed ID: 15019069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro investigation of the forces exerted by eye drops and eye spray.
    Müller F; Wagner M; Neubert RH
    Pharmazie; 2005 Aug; 60(8):630-1. PubMed ID: 16124410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative intraocular levels of pilocarpine achieved with drops and repository preparations.
    Ellis PP; Riegel MA
    J Ocul Pharmacol; 1987; 3(2):121-8. PubMed ID: 3503909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation.
    Chan J; Maghraby GM; Craig JP; Alany RG
    Int J Pharm; 2007 Jan; 328(1):65-71. PubMed ID: 17092668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physico-chemical, in vitro and in vivo characterisation of polymers for ocular use.
    Hartmann V; Keipert S
    Pharmazie; 2000 Jun; 55(6):440-3. PubMed ID: 10907252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects of pilocarpine eye drop enhanced by decreasing its volume of instillation.
    Lal A; Kataria V; Rajpal A; Khanna N
    Indian J Physiol Pharmacol; 1995 Jul; 39(3):267-70. PubMed ID: 8550123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of biopharmaceutic characteristics of cromoglycate eye drops].
    Klimas R; Inkeniene AM; Briedis V; Gerbutaviciene RJ
    Medicina (Kaunas); 2003; 39 Suppl 2():96-103. PubMed ID: 14617868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical and microbiological properties of eye drops containing cefuroxime.
    Kodym A; Zawisza T; Taberska J; Kukuła H
    Acta Pol Pharm; 2006; 63(4):293-9. PubMed ID: 17203867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the influence of auxiliary substances on the physico-chemical characteristics of ophthalmic drugs. Part I. Studies on the influence of auxiliary substances on the critical micellar concentration of surfactants solutions in eye drops containing sulphacetamidum natricum.
    Pluta J; Meler J
    Acta Pol Pharm; 2002; 59(4):247-52. PubMed ID: 12403298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self assembling nanostructures for sustained ophthalmic drug delivery.
    Khopade AJ; Jain NK
    Pharmazie; 1995 Dec; 50(12):812-4. PubMed ID: 8584558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for the obtaining of increased viscosity eye drops containing amikacin.
    Sikora A; Oszczapowicz I; Tejchman B; Grzechnik M
    Acta Pol Pharm; 2005; 62(1):31-7. PubMed ID: 16022491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of pilocarpine eye drops for estimating the time since death.
    Larpkrajang S; Worasuwannarak W; Peonim V; Udnoon J; Srisont S
    J Forensic Leg Med; 2016 Apr; 39():100-3. PubMed ID: 26874433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic versus brand-name North American topical glaucoma drops.
    Mammo ZN; Flanagan JG; James DF; Trope GE
    Can J Ophthalmol; 2012 Feb; 47(1):55-61. PubMed ID: 22333853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing ceftazidime.
    Kodym A; Zawisza T; Napierała B; Kukuła H
    Acta Pol Pharm; 2006; 63(6):507-13. PubMed ID: 17438868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiglaucoma ophthalmic agents with prolonged action based on macromolecular excipients. 1. In vitro studies].
    Pergande G; Keipert S
    Pharmazie; 1990 Jul; 45(8):582-6. PubMed ID: 2080203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiglaucoma ophthalmic agents with prolonged action with based on macromolecular excipients. 3. Optimized drop preparation on a polyacrylate base].
    Keipert S; Siebenbrodt I
    Pharmazie; 1990 Jul; 45(8):596-9. PubMed ID: 2080207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating eye drop instillation technique in glaucoma patients.
    Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T
    J Glaucoma; 2012 Mar; 21(3):189-92. PubMed ID: 21336146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.